TY - JOUR
T1 - Facilities, selection, outcome measurement, and limitations of therapeutic plasma exchange for neuroimmunological disorders
T2 - The South East Asian survey study
AU - Rattanathamsakul, Natthapon
AU - Siritho, Sasitorn
AU - Viswanathan, Shanthi
AU - Hiew, Fu Liong
AU - Apiwattanakul, Metha
AU - Tan, Kevin
AU - Thirugnanam, Umapathi N.
AU - Yeo, Tianrong
AU - Quek, Amy M.L.
AU - Estiasari, Riwanti
AU - Remli, Rabani
AU - Aye, Seinn Mya Mya
AU - Ohnmar, Ohnmar
AU - Hoang, Nghia T.T.
AU - Pasco, Paul M.
N1 - Publisher Copyright:
© 2023 Wiley Periodicals LLC.
PY - 2023/8
Y1 - 2023/8
N2 - Introduction: Therapeutic plasma exchange (TPE) for neuroimmunological disorders has played an important role in the Southeast Asian region. This study investigates the challenges of performing TPE within the region. Method: A questionnaire-based survey was conducted and launched to 15 South East Asian Therapeutic Plasma Exchange Consortium (SEATPEC) members from seven countries in January 2021. It included demographics, TPE techniques, indications, challenges, timing, outcome measurement, and access to laboratory testing in each local center. Results: A total of 15 neurologists from 12 participating centers were included. They usually perform five sessions of TPE (100.0%), with 1 to 1.5 plasma volume (93.3%), and exchanges via the central catheter (100.0%). Acute relapses of neuromyelitis optica spectrum disorder and myasthenia gravis are the most common indications. They used a combination of normal saline and 5% albumin (60.0%) as replacement fluid. Most (66.7%) used TPE as an add-on treatment in steroid-refractory cases or as first-line treatment for severe attacks. They suggested assessing the TPE efficacy of TPE by the interval to the next attack, post-TPE relapse rates, and TPE-related complications. The major challenges within our region are expense, reimbursibility, and access to TPE. Conclusion: Although countrywise differences exist, all share similarities regarding methods, indications, timing, obstacles, and challenges of TPE for neuroimmunological conditions. Regional collaboration will be essential to identify strategies to reduce these barriers to access to TPE in the future.
AB - Introduction: Therapeutic plasma exchange (TPE) for neuroimmunological disorders has played an important role in the Southeast Asian region. This study investigates the challenges of performing TPE within the region. Method: A questionnaire-based survey was conducted and launched to 15 South East Asian Therapeutic Plasma Exchange Consortium (SEATPEC) members from seven countries in January 2021. It included demographics, TPE techniques, indications, challenges, timing, outcome measurement, and access to laboratory testing in each local center. Results: A total of 15 neurologists from 12 participating centers were included. They usually perform five sessions of TPE (100.0%), with 1 to 1.5 plasma volume (93.3%), and exchanges via the central catheter (100.0%). Acute relapses of neuromyelitis optica spectrum disorder and myasthenia gravis are the most common indications. They used a combination of normal saline and 5% albumin (60.0%) as replacement fluid. Most (66.7%) used TPE as an add-on treatment in steroid-refractory cases or as first-line treatment for severe attacks. They suggested assessing the TPE efficacy of TPE by the interval to the next attack, post-TPE relapse rates, and TPE-related complications. The major challenges within our region are expense, reimbursibility, and access to TPE. Conclusion: Although countrywise differences exist, all share similarities regarding methods, indications, timing, obstacles, and challenges of TPE for neuroimmunological conditions. Regional collaboration will be essential to identify strategies to reduce these barriers to access to TPE in the future.
KW - limitation
KW - neuroimmunological disorders
KW - SEATPEC
KW - South East Asia
KW - therapeutic plasma exchange
UR - http://www.scopus.com/inward/record.url?scp=85150515045&partnerID=8YFLogxK
U2 - 10.1002/jca.22047
DO - 10.1002/jca.22047
M3 - Article
C2 - 36896493
AN - SCOPUS:85150515045
SN - 0733-2459
VL - 38
SP - 437
EP - 446
JO - Journal of Clinical Apheresis
JF - Journal of Clinical Apheresis
IS - 4
ER -